Ethyl loflazepate

Identification

Name
Ethyl loflazepate
Accession Number
DB01545
Type
Small Molecule
Groups
Approved, Illicit
Description
Not Available
Structure
Thumb
Synonyms
  • Meilax
International/Other Brands
Azutolem (Takata Seiyaku) / Bigson (Hyun Dai) / Medetax (Medisa Shinyaku) / Meilax (Meiji) / Ronlax (Shiono Kemikaru) / Sukarnase (Towa Yakuhin) / Victan (Sanofi-Aventis)
Categories
UNII
VJB5FW9W9J
CAS number
29177-84-2
Weight
Average: 360.767
Monoisotopic: 360.067698236
Chemical Formula
C18H14ClFN2O3
InChI Key
CUCHJCMWNFEYOM-UHFFFAOYSA-N
InChI
InChI=1S/C18H14ClFN2O3/c1-2-25-18(24)16-17(23)21-14-8-7-10(19)9-12(14)15(22-16)11-5-3-4-6-13(11)20/h3-9,16H,2H2,1H3,(H,21,23)
IUPAC Name
ethyl 7-chloro-5-(2-fluorophenyl)-2-oxo-2,3-dihydro-1H-1,4-benzodiazepine-3-carboxylate
SMILES
CCOC(=O)C1N=C(C2=CC=CC=C2F)C2=C(NC1=O)C=CC(Cl)=C2

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-NitroindazoleThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with 7-Nitroindazole.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Aceprometazine.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Agomelatine.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Alaproclate.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Ethyl loflazepate.Approved, Illicit
AllopregnanoloneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Allopregnanolone.Investigational
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Ethyl loflazepate.Approved, Illicit, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amisulpride.Approved, Investigational
AmitriptylineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amitriptyline.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Ethyl loflazepate.Approved, Illicit
AmoxapineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amoxapine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Amperozide.Experimental
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Ethyl loflazepate.Approved, Investigational
ArticaineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Articaine.Approved
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Ethyl loflazepate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Azaperone.Investigational, Vet Approved
AzelastineEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Ethyl loflazepate.Illicit
BenperidolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Benperidol.Investigational
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Ethyl loflazepate.Approved
Benzyl alcoholThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Benzyl alcohol.Approved
BrexpiprazoleThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Brexpiprazole.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Ethyl loflazepate.Approved, Illicit
BromisovalThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Bromisoval.Experimental
BromperidolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Bromperidol.Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Brompheniramine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Brotizolam.Approved, Investigational, Withdrawn
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Ethyl loflazepate.Approved, Investigational
BuprenorphineEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Ethyl loflazepate.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Ethyl loflazepate.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Ethyl loflazepate.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Ethyl loflazepate.Approved, Illicit, Vet Approved
CanertinibThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Canertinib.Investigational
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Ethyl loflazepate.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Ethyl loflazepate.Illicit, Investigational, Vet Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Carisoprodol.Approved
CetirizineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Cetirizine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Ethyl loflazepate.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Ethyl loflazepate.Approved, Investigational, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Ethyl loflazepate.Approved
ChlorphenamineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Chlorphenamine.Approved
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Ethyl loflazepate.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Ethyl loflazepate.Approved, Investigational, Withdrawn
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Chlorzoxazone.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Ethyl loflazepate.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Citalopram.Approved
ClemastineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clemastine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with clomethiazole.Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clomipramine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clonazepam.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clonidine.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clopenthixol.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Ethyl loflazepate.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Clothiapine.Experimental
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Ethyl loflazepate.Approved
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Ethyl loflazepate.Approved, Illicit
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Ethyl loflazepate.Approved, Illicit
CyclizineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Cyclizine.Approved
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Ethyl loflazepate.Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Cyproheptadine.Approved
DantroleneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dantrolene.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Ethyl loflazepate.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dapoxetine.Investigational
DeramciclaneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Deramciclane.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Ethyl loflazepate.Approved
DesipramineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Desvenlafaxine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Detomidine.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dexbrompheniramine.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Ethyl loflazepate.Approved, Vet Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Ethyl loflazepate.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Ethyl loflazepate.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Ethyl loflazepate.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Ethyl loflazepate.Approved, Illicit, Vet Approved
Diethyl etherThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Diethyl ether.Experimental
DifenoxinThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Difenoxin.Approved, Illicit
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Ethyl loflazepate.Approved, Illicit
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Ethyl loflazepate.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dihydromorphine.Experimental, Illicit
DimenhydrinateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Ethyl loflazepate.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Ethyl loflazepate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Dixyrazine.Experimental
DoramectinThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Doramectin.Vet Approved
DoxepinThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Doxepin.Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Drotebanol.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Duloxetine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Ethyl loflazepate.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Ethyl loflazepate.Experimental, Illicit
EcopipamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ecopipam.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Efavirenz.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Eltanolone.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Ethyl loflazepate.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Entacapone.Approved, Investigational
EscitalopramThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Escitalopram.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Ethyl loflazepate.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Ethyl loflazepate.Approved
EthanolEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Ethyl loflazepate.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethyl carbamate.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ethyl chloride.Experimental, Investigational
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Ethyl loflazepate.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Etifoxine.Investigational, Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Ethyl loflazepate.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Ethyl loflazepate.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ezogabine.Approved
FelbamateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Felbamate.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Ethyl loflazepate.Approved, Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Ethyl loflazepate.Approved, Illicit, Investigational, Vet Approved
FexofenadineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fexofenadine.Approved
FlibanserinThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Flibanserin.Approved
FluanisoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluanisone.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fludiazepam.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Flunarizine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Ethyl loflazepate.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluoxetine.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Ethyl loflazepate.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Ethyl loflazepate.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Ethyl loflazepate.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fluticasone propionate.Approved
FluvoxamineThe risk or severity of adverse effects can be increased when Fluvoxamine is combined with Ethyl loflazepate.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Fospropofol.Approved, Illicit, Investigational
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Ethyl loflazepate.Approved, Investigational
Gabapentin EnacarbilThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Gabapentin Enacarbil.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Ethyl loflazepate.Approved, Illicit, Investigational
GepironeThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Ethyl loflazepate.Approved, Illicit
GuanfacineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Ethyl loflazepate.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Ethyl loflazepate.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Ethyl loflazepate.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Ethyl loflazepate.Approved, Illicit, Investigational
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Ethyl loflazepate.Approved
HydrocodoneEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Ethyl loflazepate.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved
IloperidoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Iloperidone.Approved
ImipramineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Imipramine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Indiplon.Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Ethyl loflazepate.Approved, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Ethyl loflazepate.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ketobemidone.Approved, Investigational
LamotrigineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Lamotrigine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Ethyl loflazepate.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levocetirizine.Approved
LevodopaThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levodopa.Approved
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Ethyl loflazepate.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Levomilnacipran.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Ethyl loflazepate.Approved
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Ethyl loflazepate.Approved, Vet Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Ethyl loflazepate.Approved
LofentanilThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Lofentanil.Illicit
LoprazolamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Loprazolam.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Loratadine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Ethyl loflazepate.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Lormetazepam.Approved
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Ethyl loflazepate.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Ethyl loflazepate.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Vet Approved
MaprotilineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Maprotiline.Approved
MebicarThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Mebicar.Experimental
MeclizineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Meclizine.Approved
MedazepamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Medazepam.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Medetomidine.Vet Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Ethyl loflazepate.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Melperone.Approved, Investigational
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Ethyl loflazepate.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Ethyl loflazepate.Approved, Illicit
MeptazinolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Ethyl loflazepate.Approved, Investigational
MetaxaloneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Metaxalone.Approved
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Ethyl loflazepate.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Ethyl loflazepate.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Ethyl loflazepate.Approved
MethotrimeprazineEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Ethyl loflazepate.Approved, Investigational, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methsuximide.Approved
MethylecgonineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methylecgonine.Experimental
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Ethyl loflazepate.Approved
MetyrosineEthyl loflazepate may increase the sedative activities of Metyrosine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Ethyl loflazepate.Approved, Illicit
MilnacipranThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Investigational
MirtazapineEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Molindone.Approved
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Ethyl loflazepate.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved, Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Ethyl loflazepate.Approved
NefazodoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Nefazodone.Approved, Withdrawn
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Ethyl loflazepate.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Ethyl loflazepate.Approved, Vet Approved
NorfluraneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Norflurane.Investigational
NormethadoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Nortriptyline.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Ethyl loflazepate.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Olopatadine.Approved
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Ethyl loflazepate.Approved
OpiumThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Opium.Approved, Illicit
OrphenadrineEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Osanetant.Investigational
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Ethyl loflazepate.Approved
OxethazaineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Oxethazaine.Approved, Investigational
OxprenololThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Ethyl loflazepate.Approved
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Ethyl loflazepate.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Ethyl loflazepate.Approved, Investigational, Vet Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Ethyl loflazepate.Approved
ParaldehydeEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Paroxetine.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Penfluridol.Experimental
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Ethyl loflazepate.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Ethyl loflazepate.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved
PerazineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Perazine.Investigational
PerospironeThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Perospirone.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Ethyl loflazepate.Approved
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Ethyl loflazepate.Approved
PhenazocineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Phenazocine.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Phenibut.Experimental
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Ethyl loflazepate.Approved
PhenoperidineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Phenoperidine.Experimental
PhenoxyethanolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Phenoxyethanol.Approved
PhenytoinThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Phenytoin.Approved, Vet Approved
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Ethyl loflazepate.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pipamperone.Approved, Investigational
PipotiazineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pipotiazine.Approved, Investigational
PiritramideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pomalidomide.Approved
PramipexoleEthyl loflazepate may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Prazepam.Approved, Illicit
PregabalinThe therapeutic efficacy of Ethyl loflazepate can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Ethyl loflazepate.Approved
PrimidoneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Ethyl loflazepate.Approved, Investigational, Vet Approved
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Ethyl loflazepate.Approved, Vet Approved
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Ethyl loflazepate.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Promethazine.Approved
PropanididThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Propanidid.Experimental
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Ethyl loflazepate.Approved, Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Ethyl loflazepate.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Propoxycaine.Approved
ProtriptylineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Protriptyline.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Proxibarbal.Experimental
PSD502The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with PSD502.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Ethyl loflazepate.Approved, Illicit
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Ethyl loflazepate.Approved
QuinisocaineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Quinisocaine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Raclopride.Investigational
RamelteonThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ramelteon.Approved, Investigational
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Ethyl loflazepate.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Ethyl loflazepate.Approved, Withdrawn
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Ethyl loflazepate.Approved, Investigational
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Ethyl loflazepate.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ritanserin.Investigational
RomifidineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Romifidine.Vet Approved
RopiniroleEthyl loflazepate may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Ethyl loflazepate.Approved
RotigotineEthyl loflazepate may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Ethyl loflazepate.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Ethyl loflazepate.Approved, Vet Approved
SepranoloneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Sepranolone.Investigational
SertindoleThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Ethyl loflazepate.Approved, Vet Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved
StiripentolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Ethyl loflazepate.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Ethyl loflazepate.Approved, Investigational
SultoprideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Sultopride.Experimental
SuvorexantEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TandospironeThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tasimelteon.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Ethyl loflazepate.Approved
TetrabenazineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetracaine.Approved, Vet Approved
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetrahydropalmatine.Investigational
TetrodotoxinThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tetrodotoxin.Investigational
ThalidomideEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Ethyl loflazepate.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Ethyl loflazepate.Approved, Vet Approved
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Ethyl loflazepate.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Ethyl loflazepate.Approved
TiagabineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tiapride.Approved, Investigational
TiletamineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tiletamine.Vet Approved
TilidineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tizanidine.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tolcapone.Approved, Withdrawn
TopiramateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Topiramate.Approved
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Ethyl loflazepate.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Ethyl loflazepate.Approved
TrazodoneThe risk or severity of adverse effects can be increased when Trazodone is combined with Ethyl loflazepate.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Ethyl loflazepate.Approved
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Tricaine methanesulfonate.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trichloroethylene.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Ethyl loflazepate.Approved
TrifluperidolThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trifluperidol.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Ethyl loflazepate.Approved, Vet Approved
TrimipramineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Trimipramine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Triprolidine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Ethyl loflazepate.Approved, Investigational
VenlafaxineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Venlafaxine.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Veralipride.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Vigabatrin.Approved
Vinyl etherThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Vinyl ether.Experimental
VortioxetineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Vortioxetine.Approved
XenonThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Xenon.Experimental
XylazineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Xylazine.Vet Approved
YohimbineThe therapeutic efficacy of Ethyl loflazepate can be decreased when used in combination with Yohimbine.Approved, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Ethyl loflazepate.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Ethyl loflazepate.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zolazepam.Vet Approved
ZolpidemEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Ethyl loflazepate.Approved
ZotepineThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Zotepine.Approved, Investigational
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Ethyl loflazepate.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

British Patent 1,538,165.

General References
Not Available
External Links
KEGG Drug
D01293
PubChem Compound
3299
PubChem Substance
46507486
ChemSpider
3183
ChEBI
31573
ChEMBL
CHEMBL1213460
Wikipedia
Ethyl_loflazepate
ATC Codes
N05BA18 — Ethyl loflazepate

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)196British Patent 1,538,165.
Predicted Properties
PropertyValueSource
Water Solubility0.00525 mg/mLALOGPS
logP3.36ALOGPS
logP3.85ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)9.51ChemAxon
pKa (Strongest Basic)-1.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area67.76 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity92.41 m3·mol-1ChemAxon
Polarizability35.03 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9536
Caco-2 permeable+0.5691
P-glycoprotein substrateSubstrate0.5
P-glycoprotein inhibitor INon-inhibitor0.6872
P-glycoprotein inhibitor IINon-inhibitor0.9383
Renal organic cation transporterNon-inhibitor0.8524
CYP450 2C9 substrateNon-substrate0.7542
CYP450 2D6 substrateNon-substrate0.8622
CYP450 3A4 substrateSubstrate0.5122
CYP450 1A2 substrateInhibitor0.7947
CYP450 2C9 inhibitorNon-inhibitor0.5444
CYP450 2D6 inhibitorNon-inhibitor0.9018
CYP450 2C19 inhibitorInhibitor0.6447
CYP450 3A4 inhibitorNon-inhibitor0.7437
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5303
Ames testNon AMES toxic0.6532
CarcinogenicityNon-carcinogens0.6
BiodegradationNot ready biodegradable1.0
Rat acute toxicity1.5886 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9977
hERG inhibition (predictor II)Non-inhibitor0.8853
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Mass Spectrum (Electron Ionization)MSsplash10-0670-1941000000-427495e16cf17300345d
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as alpha amino acid esters. These are ester derivatives of alpha amino acids.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acid esters
Alternative Parents
1,4-benzodiazepines / Fluorobenzenes / 1,3-dicarbonyl compounds / Aryl chlorides / Aryl fluorides / Secondary carboxylic acid amides / Carboxylic acid esters / Lactams / Ketimines / Propargyl-type 1,3-dipolar organic compounds
show 7 more
Substituents
Alpha-amino acid ester / Benzodiazepine / 1,4-benzodiazepine / Fluorobenzene / Halobenzene / Aryl chloride / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Benzenoid
show 24 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Drug created on July 31, 2007 07:10 / Updated on December 01, 2017 14:45